Dr. Frydenberg discusses MRI’s potential as a screening tool
Mark Frydenberg, MD, of Australia's Monash University, discusses whether multiparametric MRI is ready to be used as a screening modality for prostate cancer.
Is multiparametric MRI at a point where urologists could use it as a screening modality for prostate cancer? In this interview, Mark Frydenberg, MD, of Monash University in Melbourne, Victoria, Australia, addresses this question and how the use of MRI is changing.
Also see - PET use in prostate cancer widens, but questions remain: An interview with Mark Frydenberg, MD
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.
